Meeting
2020 ASCO Virtual Scientific Program
Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.
Authors
Amer Methqal Zeidan
Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT
Amer Methqal Zeidan , Guillermo Garcia-Manero , Amy Elizabeth Dezern , Pierre Fenaux , Peter L. Greenberg , Michael R. Savona , Joseph G. Jurcic , Amit Verma , Ghulam J. Mufti , Rena Buckstein , Valeria Santini , Abderrahmane Laadem , Jennie Zhang , Anita Rampersad , Daniel Sinsimer , Chrystal Ursula Louis , Peter G. Linde , Alan F. List , Mikkael A. Sekeres
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myelodysplastic Syndromes (MDS)
Clinical Trial Registration Number
NCT02631070
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7554)
DOI
10.1200/JCO.2020.38.15_suppl.7554
Abstract #
7554
Poster Bd #
327
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.
First Author: Amer Methqal Zeidan
Poster
2023 ASCO Annual Meeting
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
First Author: Aaron Thomas Gerds
Poster
2023 ASCO Annual Meeting
A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).
First Author: Yi Zhang
Poster
2020 ASCO Virtual Scientific Program
Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).
First Author: Rami S. Komrokji